Rabeprazole Gastro-Resistant Tablet 20mg
Rabeprazole 20mg gastro-resistant tablet — same irreversible H⁺/K⁺-ATPase proton pump inhibitor mechanism with the distinctive rabeprazole pharmacological advantages: higher pKa (faster activation), greater CYP2C19 independence (more consistent acid suppression across metaboliser phenotypes), and superior nocturnal acid control. The gastro-resistant coating protects against gastric acid degradation. See SOUNDRAB™ DSR for full rabeprazole mechanism detail.
Standalone rabeprazole 20mg for acid-related conditions where a prokinetic is not required: peptic ulcer disease, GORD and reflux oesophagitis, H. pylori eradication (PPI component of triple therapy), NSAID-associated ulcer prevention, laryngopharyngeal reflux, and Zollinger-Ellison syndrome. Preferred over omeprazole in patients with documented CYP2C19 rapid metaboliser status or inadequate response to omeprazole. 2-year expiry supports extended stocking.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
SOUNDRAB 20 standalone provides the rabeprazole PPI option for prescribers who want the CYP2C19-independent acid suppression advantage of rabeprazole without the fixed domperidone combination — important when prescribing rabeprazole as the PPI component of H. pylori triple therapy or as monotherapy for peptic ulcer disease where prokinetic co-therapy is not indicated.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.